<DOC>
	<DOCNO>NCT00105170</DOCNO>
	<brief_summary>This Phase I , open-label , dose-escalation study subject advance solid tumor . This first study hCBE-11 human design determine safety well patient tolerate investigational drug . The study duration two year treatment visit occur weekly either 4 8 week , follow-up 8 week long-term follow-up contact every 3 month thereafter .</brief_summary>
	<brief_title>Safety Tolerability hCBE-11 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed refractory solid tumor curable standard therapy . At least one measurable lesion ECOG Performance Status less equal 2 Acceptable hematologic status Albumin great equal 2.5 g/dL Normal calculate glomerular filtration rate ( GFR ) Acceptable liver function Uncontrolled cardiac disease , angina , congestive heart failure , myocardial infarction within 6 month prior Study Day Known history hepatitis B C , HIV infection Clinically significant effusion , include pericardial , pleural , ascites Serious nonmalignant disease Central nervous system ( CNS ) metastatic involvement except disease successfully treat Investigational therapy within 4 week Study Day 1 Radiation therapy tumor follow study Chemotherapy , biologic therapy , major surgery diagnostic within 4 week prior Study Day 1 Current Grade 3 4 neurological toxicity Concurrent antineoplastic therapy and/or steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Tumors</keyword>
	<keyword>hCBE-11</keyword>
</DOC>